ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions
Jump to:  View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 0266
    E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
  • Abstract Number: 1853
    Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care
  • Abstract Number: L08
    Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation
  • Abstract Number: 0853
    Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System
  • Abstract Number: 1490
    Early Experience with SGLT2i in Systemic Lupus Erythematosus
  • Abstract Number: 1424
    Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients
  • Abstract Number: 2228
    Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment
  • Abstract Number: 0649
    Early Systemic Sclerosis Definitions: Time to Rethink ‘Early’ in SSc Disease?
  • Abstract Number: 0470
    Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic
  • Abstract Number: 2284
    Effect of Air Pollutant Exposure on Disease Activity of Systemic Lupus Erythematous: A Prospective Longitudinal Study from Korea
  • Abstract Number: 1891
    Effect of Apremilast on Disease Interception in Patients with Psoriasis at Increased Risk of Developing PsA – Results of the Prospective Interventional Epos Trial
  • Abstract Number: 1413
    Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST
  • Abstract Number: 2478
    Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
  • Abstract Number: 1982
    Effect of Denosumab on Knee Pain and Bone Marrow Lesions in Symptomatic Knee Osteoarthritis
  • Abstract Number: 2549
    Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT
  • Abstract Number: 1963
    Effect of JAK-STAT Inhibition by Baricitinib and Tofacitinib on Disease Phenotype in a Mouse Model of Myositis
  • Abstract Number: 2316
    Effect of SARS-CoV2 Infection on Disease Flares in Patients with Systemic Lupus Erythematosus: A Case-control Study
  • Abstract Number: 0522
    Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status
  • Abstract Number: 2317
    Effect of SLE-DAS Remission on Quality of Life in Patients with Systemic Lupus Erythematosus: A Cross-sectional Validation Study
  • Abstract Number: 1321
    Effect of Subcutaneous Local Anaesthesia Prior to Intra-Articular Injection: An Open Label, Paired-group, Randomized Controlled Trial
  • Abstract Number: 1831
    Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia
  • Abstract Number: 0042
    Effect of the Inflammatory Microenvironment Induced by Monocytes on Fibroblasts and Modulatory Action of Human Dental Pulp Stem Cells
  • Abstract Number: 1337
    Effect of Tofacitinib Therapy on Angiotensin Converting Enzyme Activity in Rheumatoid Arthritis
  • Abstract Number: 1584
    Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study
  • Abstract Number: 1361
    Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers
  • Abstract Number: 2311
    Effect on Lupus Outcomes of the Protective Allele at rs1876453 in the Complement Receptor 2 Gene
  • Abstract Number: 0806
    Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial
  • Abstract Number: 0775
    Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study
  • Abstract Number: 2418
    Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment
  • Abstract Number: 1335
    Effectiveness of Longstanding Exercise Therapy versus Usual Care in People with Rheumatoid Arthritis and Severe Functional Limitations: A Randomized Controlled Trial (L-EXTRA)
  • Abstract Number: 0215
    Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
  • Abstract Number: 0497
    Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis
  • Abstract Number: 2003
    Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis
  • Abstract Number: 0531
    Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis
  • Abstract Number: 1414
    Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis
  • Abstract Number: 0956
    Effects of B Cell Depletion by CD19-targeted CAR-T Cells in a Murine Model of Systemic Sclerosis
  • Abstract Number: 0434
    Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-
  • Abstract Number: 1990
    Effects of Exercise on Movement-Evoked Pain in People with Knee Osteoarthritis
  • Abstract Number: 0903
    Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
  • Abstract Number: 2007
    Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study
  • Abstract Number: 1679
    Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
  • Abstract Number: 1327
    Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials
  • Abstract Number: 2151
    Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial
  • Abstract Number: 2153
    Effects of One-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis
  • Abstract Number: 0821
    Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post Hoc Analysis of the FORWARD Study
  • Abstract Number: 1105
    Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients
  • Abstract Number: 0688
    Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
  • Abstract Number: 1197
    Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial
  • Abstract Number: 2488
    Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial
  • Abstract Number: 0244
    Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
  • Abstract Number: 0685
    Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
  • Abstract Number: L14
    Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study
  • Abstract Number: 2463
    Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients
  • Abstract Number: 2545
    Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study
  • Abstract Number: 0776
    Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
  • Abstract Number: 1344
    Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice
  • Abstract Number: L09
    Efficacy and Safety of LNK01001 in Chinese Patients with Moderate to Severe Active Rheumatoid Arthritis with an Inadequate Response to Conventional Synthetic DMARDs: 24-week Results from a Phase 2 Trial
  • Abstract Number: 0674
    Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
  • Abstract Number: 0839
    Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study
  • Abstract Number: 1518
    Efficacy and Safety of Prostaglandins Analogues in Systemic Sclerosis-associated Raynaud’s Phenomenon. a Systematic Review and Meta-Analysis
  • Abstract Number: 0372
    Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
  • Abstract Number: L03
    Efficacy and Safety of Targeted Therapies in VEXAS Syndrome: Retrospective Study from the French VEXAS Group
  • Abstract Number: 2569
    Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
  • Abstract Number: 1569
    Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study
  • Abstract Number: 1425
    Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
  • Abstract Number: 2326
    Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
  • Abstract Number: L12
    Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
  • Abstract Number: 2165
    Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up
  • Abstract Number: 0597
    Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study
  • Abstract Number: 2191
    Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease
  • Abstract Number: 1041
    Efficacy of Apremilast on Peripheral and Axial Inflammation in Patients with Psoriatic Arthritis Based on Whole-Body Magnetic Resonance Imaging
  • Abstract Number: 2347
    Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials
  • Abstract Number: 0608
    Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study
  • Abstract Number: 0524
    Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
  • Abstract Number: 1937
    Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis
  • Abstract Number: 2143
    Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study
  • Abstract Number: 1510
    Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in Women with Systemic Lupus Erythematosus (SLE) Receiving Cyclophosphamide (CYC)
  • Abstract Number: 1438
    Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA
  • Abstract Number: 0716
    Efficacy of Immunosuppressants for Disease Relapse in Patients with IgG4-related Disease at Our Institution
  • Abstract Number: 1861
    Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
  • Abstract Number: 2156
    Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study
  • Abstract Number: 1215
    Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
  • Abstract Number: 2000
    Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study
  • Abstract Number: 1418
    Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial
  • Abstract Number: 1382
    Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome
  • Abstract Number: 1427
    Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials
  • Abstract Number: 0818
    Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial
  • Abstract Number: 0309
    Efficacy, Safety, Pharmacokinetics and Immunogenicity of Repeated Dosing of GSK3858279 in Patients with Knee Osteoarthritis: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study
  • Abstract Number: 1322
    Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
  • Abstract Number: 0988
    Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
  • Abstract Number: 0422
    Electronic Health Record-Based Machine Learning Model for Predicting Disease Activity in Patients with Rheumatoid Arthritis
  • Abstract Number: 0055
    Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses
  • Abstract Number: 1315
    Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies
  • Abstract Number: 0558
    Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment
  • Abstract Number: 2475
    Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders
  • Abstract Number: 1497
    Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications
  • Abstract Number: 1025
    Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients
  • Abstract Number: 1836
    Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium
  • Abstract Number: 2556
    End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort
  • Abstract Number: 2454
    Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study
  • Abstract Number: 2028
    Endorsement of Core Domain Definitions to Measure the Impact of Glucocorticoids in Patients with Rheumatic Diseases: A Report from the OMERACT Working Group on Glucocorticoid Impact
  • Abstract Number: 1717
    Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis
  • Abstract Number: 1665
    Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis
  • Abstract Number: 1095
    Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures
  • Abstract Number: 1049
    Enhanced Diagnostic Confidence with High Frequency Temporal Artery Ultrasound in Diagnosis of Cranial Giant Cell Arteritis (GCA)
  • Abstract Number: 2084
    Enhancing Internal Medicine Curriculum: Key Rheumatology Themes in Inpatient Setting
  • Abstract Number: 0868
    Enhancing Oxidative Phosphorylation Through PDK2 Depletion Alleviates Cartilage Degradation in Surgically Induced Osteoarthritis
  • Abstract Number: 0576
    Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers
  • Abstract Number: 0039
    Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis
  • Abstract Number: 2309
    Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 2376
    Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis
  • Abstract Number: 1546
    Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
  • Abstract Number: L04
    EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis
  • Abstract Number: 1552
    Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France
  • Abstract Number: 2391
    Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register
  • Abstract Number: 0126
    Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population
  • Abstract Number: 2281
    Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study
  • Abstract Number: 1535
    Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study
  • Abstract Number: 1589
    Epigenetic Regulation of DNMT3A by TFEB and DOT1L Through AMPK Signalling Orchestrates the Lysosomal Response of Macrophages During Gout and Clonal Hematopoiesis
  • Abstract Number: 0907
    Epstein Barr Virus Reactivation May Associate with Transition from Incomplete to Systemic Lupus Erythematosus
  • Abstract Number: 1704
    Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma
  • Abstract Number: 0365
    Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges
  • Abstract Number: 0652
    Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease
  • Abstract Number: 0761
    EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD)
  • Abstract Number: 1648
    EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice: 2023 Update
  • Abstract Number: 1115
    EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice
  • Abstract Number: 1245
    Evaluating a Diagnostic Algorithm for Childhood Sjögren’s Disease
  • Abstract Number: 0639
    Evaluating Esophageal Dysmotility by Scintigraphy in Systemic Sclerosis: Subsets and Phenotypes
  • Abstract Number: 2269
    Evaluating Global Patterns in Treatment and Prevalence of Glucocorticoid Related Comorbidities in Systemic Lupus Erythematosus: An International Study
  • Abstract Number: 1189
    Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis
  • Abstract Number: 0658
    Evaluating the Associations Between Autonomic Dysfunction, Clinical Phenotype and Gastrointestinal Transit in Patients with Systemic Sclerosis
  • Abstract Number: 0555
    Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists
  • Abstract Number: 2061
    Evaluation of a Tool to Enhance Training of the Physical Examination of the Temporomandibular Joint (TM Joint) in Juvenile Idiopathic Arthritis (JIA)
  • Abstract Number: 1168
    Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)
  • Abstract Number: 0582
    Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial
  • Abstract Number: 1954
    Evaluation of Cancer Screening Methods in Patients Diagnosed with Inflammatory Muscle Disease at Kansas University Medical Center
  • Abstract Number: 1451
    Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience
  • Abstract Number: 1320
    Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept
  • Abstract Number: 1834
    Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort
  • Abstract Number: 0174
    Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
  • Abstract Number: 1972
    Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial
  • Abstract Number: 1103
    Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy
  • Abstract Number: 1449
    Evaluation of Progression from Preclinical to Systemic Autoimmune Rheumatic Disease
  • Abstract Number: 2106
    Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls
  • Abstract Number: 2412
    Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice
  • Abstract Number: 1860
    Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis
  • Abstract Number: 1540
    Evaluation of the Validity of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Antineutrophil Cytoplasmic Antibody-associated Vasculitis for an Asian Population on the Basis of the Patterns of Organ Involvement
  • Abstract Number: 2183
    Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients
  • Abstract Number: 1526
    Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study
  • Abstract Number: 1670
    Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae
  • Abstract Number: 1859
    Examining Hydroxychloroquine Prescribing and SLE Damage in a Statewide Lupus Cohort
  • Abstract Number: 1226
    Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus
  • Abstract Number: 1402
    Exceeding Activity Targets but Missing the Mark with Sleep: Mapping 24-Hour Movement Guidelines in Axial Spondyloarthritis
  • Abstract Number: 0084
    Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
  • Abstract Number: 1159
    Expanded Cytotoxic CD8+ T Cell Clones Characterize the Blood of Inclusion Body Myositis Patients
  • Abstract Number: 0003
    Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease
  • Abstract Number: 2124
    Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals
  • Abstract Number: 1790
    Expansion of CD8+ TCRVβ9+ T Cells in the Peripheral Blood of HLA-B27+ Patients with Axial Spondyloarthritis
  • Abstract Number: 2582
    Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
  • Abstract Number: 0199
    Experience in Real-World Conditions of the Effectiveness of the Vaccine Against Herpes Zoster Virus
  • Abstract Number: 1157
    Experience of Pain in Adults with Idiopathic Inflammatory Myopathies, Myositis
  • Abstract Number: 1358
    Experiences and Attitudes Related to Assisted Reproductive Technologies Among Women with Systemic Rheumatic Disease
  • Abstract Number: 1432
    Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions
  • Abstract Number: 0726
    Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs
  • Abstract Number: 2267
    Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 2157
    Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis
  • Abstract Number: 1740
    Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers
  • Abstract Number: 2020
    Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice
  • Abstract Number: 2218
    Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients
  • Abstract Number: 1830
    Exploring Psychosocial Characteristics of Youth with Chronic Pain Across Gender Identities
  • Abstract Number: 0479
    Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry
  • Abstract Number: 1133
    Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center
  • Abstract Number: 1825
    Exploring the Health and Cannabis Use Among Young and Middle-Aged Adults with Rheumatologic Conditions in Alberta, Canada
  • Abstract Number: 2424
    Exploring the Limit of Image Resolution for Human Expert Classification of Vascular Ultrasound Images in Giant Cell Arteritis and Healthy Subjects: The GCA-US-AI Project
  • Abstract Number: 1719
    Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway
  • Abstract Number: 1791
    Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622
  • Abstract Number: 0270
    Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety
  • Abstract Number: 2065
    Exploring the Power of Ultrasound in Rheumatology: Insights from Young Rheumatologists in Mexico
  • Abstract Number: 1069
    Exploring the Risk of Demyelination Associated with TNF Alpha Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)
  • Abstract Number: 1643
    Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis
  • Abstract Number: 1566
    Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
  • Abstract Number: 0083
    Expression of mRNA Vaccine Antigen in Hematopoietic Cells Is Necessary for Induction of Optimal Vaccine-Specific CD4+ T Cell Responses
  • Abstract Number: 0791
    Expression of TL1A, Inflammatory, and Fibrotic Pathways in Patients with Diffuse Systemic Sclerosis
  • Abstract Number: 1988
    Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis
  • Abstract Number: 0140
    Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
  • Abstract Number: 1194
    Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain
  • Abstract Number: 1223
    Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis
  • Abstract Number: 1365
    Extraglandular Involvement and Autoantibody Status as Risk Factors for Cardiovascular Disease in Primary Sjogren’s Syndrome (pSS): A 20 Year-follow up Study
Jump to:  View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology